APM
FATE icon

Avidity Partners Management’s Fate Therapeutics FATE Stock Holding History

Avidity Partners Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-104,653
Closed -$1.06M – 88
2022
Q4 		$1.06M Buy
+104,653
New +$1.97M 0.02% 79

Other funds holding FATE

State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Avidity Partners Management's FATE Position: Q1 2023 in Review

Avidity Partners Management sold out of Fate Therapeutics (FATE) in Q1 2023, closing a stake of 104,653 shares — an estimated $1.06M sold.

Avidity Partners Management first reported a position in FATE in Q4 2022 and held it in 1 quarter. The position peaked at $1.06M in Q4 2022. 181 funds tracked by Wall St. Rank hold FATE as of Q1 2023.

  • Avidity Partners Management reported no remaining Fate Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Avidity Partners Management sold 104,653 Fate Therapeutics shares in Q1 2023, an estimated $1.06M.
  • Avidity Partners Management first reported a position in Fate Therapeutics in Q4 2022 and held it in 1 quarter.
  • Avidity Partners Management's Fate Therapeutics position peaked at $1.06M in Q4 2022.
  • 181 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2023.

Based on Avidity Partners Management's 13F filing for Q1 2023, filed 15 May 2023.